The editors should be commended for attempting an extensive compilation of information on cancer markers...-New England Journal of Medicine

• Ch. 1. Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer.- Ch. 2. ras Proto-Oncogene Activation in Human Malignancy.- Ch. 3. C-myc as a Tumor Marker for Primary Human Cancers.- Ch. 4. p53 in Human Cancer.- Ch. 5. Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies.- Ch. 6. Genetic Alterations in Colon Cancer.- Ch. 7. Genetic Changes in Breast Cancer.- Ch. 8. Genetic Alterations in Lung Cancer.- Ch. 9. Wilms Tumor-Susceptibility Loci.- Ch. 10. Non-Hodgkin’s Lymphomas.- Ch. 11. Phenotypic Expression of Hodgkin’s Disease: Biologic, Immunologic, and Functional Properties of Reed-Sternberg Cells.- Ch. 12. Melanoma Markers.- Ch. 13. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma.- Ch. 14. P-Glycoproteins in Tumors.- Ch. 15. Genetically Engineered Antitumor Monoclonal Antibodies.- Ch. 16. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase.- Ch. 17. Summary and Perspective: Assessing Test Effectiveness—The Identification of Good Tumor Markers.

The editors should be commended for attempting an extensive compilation of information on cancer markers...-New England Journal of Medicine

• Ch. 1. Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer.- Ch. 2. ras Proto-Oncogene Activation in Human Malignancy.- Ch. 3. C-myc as a Tumor Marker for Primary Human Cancers.- Ch. 4. p53 in Human Cancer.- Ch. 5. Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies.- Ch. 6. Genetic Alterations in Colon Cancer.- Ch. 7. Genetic Changes in Breast Cancer.- Ch. 8. Genetic Alterations in Lung Cancer.- Ch. 9. Wilms Tumor-Susceptibility Loci.- Ch. 10. Non-Hodgkin’s Lymphomas.- Ch. 11. Phenotypic Expression of Hodgkin’s Disease: Biologic, Immunologic, and Functional Properties of Reed-Sternberg Cells.- Ch. 12. Melanoma Markers.- Ch. 13. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma.- Ch. 14. P-Glycoproteins in Tumors.- Ch. 15. Genetically Engineered Antitumor Monoclonal Antibodies.- Ch. 16. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase.- Ch. 17. Summary and Perspective: Assessing Test Effectiveness—The Identification of Good Tumor Markers.

The editors should be commended for attempting an extensive compilation of information on cancer markers...-New England Journal of Medicine

• Ch. 1. Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer.- Ch. 2. ras Proto-Oncogene Activation in Human Malignancy.- Ch. 3. C-myc as a Tumor Marker for Primary Human Cancers.- Ch. 4. p53 in Human Cancer.- Ch. 5. Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies.- Ch. 6. Genetic Alterations in Colon Cancer.- Ch. 7. Genetic Changes in Breast Cancer.- Ch. 8. Genetic Alterations in Lung Cancer.- Ch. 9. Wilms Tumor-Susceptibility Loci.- Ch. 10. Non-Hodgkin’s Lymphomas.- Ch. 11. Phenotypic Expression of Hodgkin’s Disease: Biologic, Immunologic, and Functional Properties of Reed-Sternberg Cells.- Ch. 12. Melanoma Markers.- Ch. 13. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma.- Ch. 14. P-Glycoproteins in Tumors.- Ch. 15. Genetically Engineered Antitumor Monoclonal Antibodies.- Ch. 16. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase.- Ch. 17. Summary and Perspective: Assessing Test Effectiveness—The Identification of Good Tumor Markers.